ERBB2 and neoplasm: We next performed an analysis to identify genes responsible for HER2 oncogenic signalling pathway and response to trastuzumab therapy among the 2 HER2 IHC classes (HER2 IHC 3+ and 2 + /Amplified) as well as in the 2 + /non-amplified tumours.